IN BRIEF: Diurnal's Efmody adrenal treatment launches in UK

Mon, 13th Sep 2021 20:23

Diurnal Group PLC - Cardiff, Wales-based pharmaceutical company focused on hormonal diseases - Launches of Efmody in the UK as treatment of adult and adolescent patients with the rare condition congenital adrenal hyperplasia. The launch of Efmody follows its approval by the UK Medicines & Healthcare Products Regulatory Agency in Great Britain in July 2021.

Current stock price: 56.21 pence

Year-to-date change: down 0.5%

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Related Shares

More News

28 Oct 2022 21:18

TRADING UPDATES: SulNOx, Marwyn loss widens; Kropz gets new facility

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

21 Oct 2022 21:29

TRADING UPDATES: Trackwise Designs wins deal; Cake Box names CFO

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

14 Oct 2022 15:48

UK shareholder meetings calendar - next 7 days

7 Oct 2022 13:01

Diurnal treatment gets approval from Welsh regulatory body

(Alliance News) - Diurnal Group PLC on Friday said its Efmody treatment has been recommended as an option to treat patients with congenital adrenal hy...

7 Oct 2022 11:31

Diurnal's 'Efmody' treatment gets thumbs-up for NHS Wales

(Sharecast News) - Specialty pharmaceutical company Diurnal Group announced on Friday that the All-Wales Medicines Strategy Group (AWMSG) has recommen...

Latest Share Chat